Home Page News Statistics API Review Formulation Monthly Im&Ex report All Information
     
Keyword:
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
　　Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Conference on ...
Information Release...
Internationalization&nbs...
Welcome to Pro...
Healthoo.com Carbap...
APIs Innovation&nbs...
China Import Export Statistics Report In...
API Export Price by ...
Tylosin Bulk Drug Export&...
China Monthly Export Stat...
China Monthly Export Stat...
China Monthly Export Stat...
Your position:www.healthoo.com >> EN >> Formulation
Oseltamivir is Gone, the Pattern of Anti-influenza Drugs is Reversed!2022-06-26
AstraZeneca Merck Jointly Release the Results of the Phase 3 Clinical Trial of Olaparib2022-06-26
Phase III Study of AstraZenecas Innovative Therapy was Successful! A Listing Application Will be Submitted2022-06-26
AstraZeneca/Mersk & Co.s MEK Inhibitor Filed for Listing in China2022-06-14
Pfizer to Increase Production Capacity of Coronavirus Oral Drugs, Invest 120 Million US Dollars2022-06-09
FDA Breakthrough Therapy Designation for Topical Vitamin A Derivatives to Treat Inherited Skin Diseases2022-06-09
4 Innovative Drugs are Expected to be Approved by the FDA in June2022-06-02
Roche to Introduce ATR Inhibitor RP-3500 for times="32".2 Billion2022-06-02
Bayer/MSD Verixiguat Approved in China to Treat Heart Failure2022-05-19
In 2021, the Total Profit of Chinas Pharmaceutical Industry will Exceed 700 Billion Yuan, a Year-on-year Increase of 67.3%2022-05-18
Emerging Industry of Medical-grade PCs Global Medical Market Expected to Generate $336 Billion in Revenue by 20252022-05-18
AstraZenecas Ultomiris Third Indication Approved by US FDA!2022-05-05
Biogen Withdraws European Marketing Application for New Alzheimers Drug Aduhelm2022-04-27
Hengrui Medicines Class 1 New Drugs Hit The 30 Billion Antithrombotic Drug Market2022-04-27
Pfizer Recalls Some Antihypertensive Drugs Due to Excessive Levels of Carcinogens2022-04-27
Top 10 Global CDMO Rankings in 20222022-04-22
Japans First! The Recombinant Protein COVID-19 Vaccine Introduced by Takeda Has Been Approved For Marketing2022-04-22
Regeneron Acquires Checkmate for $250 Million, Gets TLR9 Agonist2022-04-22
The First TCR-T Product For The Treatment of Liver Cancer Was Approved For Clinical Use2022-04-22
The First Domestic Infliximab Price Adjustment2022-04-22
Approval of The Clinical Trial Application of WuXi Giant Norricy Orenza Injection For r/r B-ALL2022-04-22
Domestic Infliximab Refreshes Low Price Again!2022-04-22
24.6 Down To .84! A Batch Of Reduced-Price Drugs Are Now Available In Pharmacies2022-04-14
The $100 billion COVID-19 drug market2022-04-07
Several Domestic New Crown Mrna Companies Turn To Developing Broad-Spectrum Vaccines, Exploring Against Different Mutant Strains2022-04-07
Paxlovid Has Entered The Clinical Treatment Of 8 Provinces In China, Expert: The Effect Is More Obvious2022-04-02
3D printing of drug tablets in as little as 7 seconds2022-03-31
Chinas Orthopaedic Surgical Robot Industry Enters The Fast Lane With Full Market Potential2022-03-29
Class II Medical Device For Specific Phobias (Agoraphobia) Approved2022-03-29
The Continuous Procurement Programme Of 47 National Varieties Has Come2022-03-29
5 Billion! Strong Growth! Top 1 Sample Hospital Variety2022-03-29
Watson Bios Bivalent HPV Vaccine Approved2022-03-29
共1508个 页次:5/48页 32个/页 首页 上一页 下一页 尾页 转到：
Our Advantages of Reports
①All reports written by ourselves
②All data having original sources
③Information is the latest
④Continuous historical data
⑤Objective analysis and remark
Purchase Flow of Reports
①Confirm purchase (If necessary sign the contract)
②Transfer payment to company's bank account
③After accepting payment we email the report to clients (PDF format)
④Send the invoice
Bank account
①Beneficiary's Name:Beijing orientbit technology ltd
②Beneficiary's Account No.:110060239018002127366
③Name of bank:Bank of Communications Beijing Branch，Fuwai Sub-Branch
④Address of bank:NO7，FUWAISTREET，XICHENG DISTRICT，BEIJING，CHINA SWIFT CODE：COMMCNSHBJG
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463